• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Cortechs.ai and EDAP Announce World's First OnQ™ Prostate-Assisted Focal One® Robotic HIFU Procedure at UCSF Prostate Cancer Center

    2/6/25 8:00:00 AM ET
    $EDAP
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $EDAP alert in real time by email
    • First Focal One® procedure utilizing Cortechs.ai's advanced MRI-imaging technology, OnQ Prostate, successfully performed at the University of California, San Francisco Prostate Cancer Center
    • OnQ Prostate's Restriction Spectrum Imaging (RSI) technology improves lesion localization and targeting for urologists performing Focal One Robotic High Intensity Focused Ultrasound (HIFU) ablation
    • Reflects EDAP's continued commitment to innovation and further validates Focal One as the leading focal therapy platform controlled by urologists  



    San Diego, CA and Austin, Texas, February 6, 2025 - Cortechs.ai, an emerging leader in novel imaging solutions for prostate cancer care, and EDAP TMS SA (NASDAQ:EDAP), the global leader in robotic energy-based therapies, today announced the successful completion of the world's first OnQ Prostate-assisted Focal One® Robotic HIFU procedure at the University of California, San Francisco (UCSF) Prostate Center. This milestone marks the first clinical application of OnQ Prostate's patented RSI technology to guide focal therapy, demonstrating how advanced MR-imaging can improve lesion localization and targeting for urologists performing focal therapy.

    As the only FDA-cleared solution for RSI-MRI, OnQ Prostate uniquely provides more detailed information about the tissue microstructure that can help urologists more confidently identify which patients are the best candidates for focal therapy and which lesions should be targeted. Additionally, OnQ Prostate integrates seamlessly into these focal therapy systems, allowing for real-time precision targeting during the procedure to maximize likelihood of successfully ablating the desired area.

    "OnQ Prostate very clearly delineated the tumor anatomy in this case, and helped us map out a relatively complex treatment plan for our focal therapy patient" said Dr. Matthew R. Cooperberg, M.D., M.P.H, Professor of Urology at the University of California, San Francisco, who performed the Focal One procedure on Tuesday, January 28th, 2025. "I am quite optimistic that this technology will help improve and standardize prostate MRI interpretation in multiple contexts across the prostate cancer journey."

    "This milestone at UCSF underscores the critical role our advanced imaging plays in empowering urologists to deliver more precise, personalized treatment," said Kyle Frye, CEO of Cortechs.ai. "We are committed to driving meaningful advancements in prostate cancer care, ensuring that both physicians and patients benefit from enhanced precision at every stage of the treatment journey."

    "We are pleased to be partnering with the Cortechs.ai team in the integration of OnQ Prostate with Focal One Robotic HIFU," said Ryan Rhodes, Chief Executive Officer of EDAP TMS. "This new clinical offering further demonstrates our ongoing commitment to expand the capabilities of Focal One to assist urologists in the delivery of a precise, patient-specific treatment to their prostate cancer patients."

    Focal therapy for prostate cancer is an emerging approach that aims to ablate clinically significant disease while preserving healthy tissue, reducing the side effects associated with whole-gland treatments. For urologists performing focal therapy, the ability to precisely localize lesions is critical to achieving successful oncologic control while minimizing damage to surrounding healthy tissue. OnQ Prostate enhances this process by enhancing lesion conspicuity, allowing for more informed patient-selection and treatment planning.

    As focal therapy becomes increasingly integrated into prostate cancer care, Cortechs.ai remains at the forefront of developing solutions that support urologists in delivering more effective, evidence-based, and minimally invasive treatment strategies.

    About Cortechs.ai

    Cortechs.ai is a leader in AI applications in radiology, leveraging advanced technologies in medical imaging to enhance disease screening and early detection, empowering healthcare providers to deliver better outcomes for patients. The company develops and markets innovative medical device software that quantifies and tracks neurodegeneration and prostate cancer, helping clinicians detect and monitor clinically significant cases. Cortechs.ai's industry-leading imaging solutions offer radiologists, oncologists, and urologists a streamlined, cost-effective way to assess prostate health, including detection and monitoring of cancer. The company also has FDA-cleared products for use in assessing neurological disorders such as Alzheimer's disease, epilepsy, multiple sclerosis, brain trauma, tumors, and other brain abnormalities. For more information, please visit www.cortechs.ai and follow us on Twitter, LinkedIn, and Facebook.

    About EDAP TMS SA

    A recognized leader in robotic energy-based therapies, EDAP TMS develops, manufactures, promotes and distributes worldwide minimally invasive medical devices for various conditions using ultrasound technology. By combining the latest technologies in imaging, robotics and precise non-invasive energy delivery, EDAP TMS introduced the Focal One® in Europe and in the U.S. as the leading prostate focal therapy controlled by urologists with the potential to expand to multiple indications beyond prostate cancer. For more information on the Company, please visit https://focalone.com.

    Forward-Looking Statements

    In addition to historical information, this press release contains forward-looking statements within the meaning of applicable federal securities laws, including Section 27A of the U.S. Securities Act of 1933 (the "Securities Act") or Section 21E of the U.S. Securities Exchange Act of 1934, which may be identified by words such as "believe," "can," "contemplate," "could," "plan," "intend," "is designed to," "may," "might," "potential," "objective," "target," "project," "predict," "forecast," "ambition," "guideline," "should," "will," "estimate," "expect" and "anticipate," or the negative of these and similar expressions, which reflect our views about future events and financial performance. Such statements are based on management's current expectations and are subject to a number of risks and uncertainties, including matters not yet known to us or not currently considered material by us, and there can be no assurance that anticipated events will occur or that the objectives set out will actually be achieved. Important factors that could cause actual results to differ materially from the results anticipated in the forward-looking statements include, among others, the clinical status and market acceptance of our HIFU devices and the continued market potential for our lithotripsy and distribution divisions, as well as risks associated with the current worldwide inflationary environment, the uncertain worldwide economic, political and financial environment, geopolitical instability, climate change and pandemics like the COVID 19 pandemic, or other public health crises, and their related impact on our business operations, including their impacts across our businesses or demand for our devices and services.



    Other factors that may cause such a difference may also include, but are not limited to, those described in the Company's filings with the Securities and Exchange Commission and in particular, in the sections "Cautionary Statement on Forward-Looking Information" and "Risk Factors" in the Company's Annual Report on Form 20-F.

    Forward-looking statements speak only as of the date they are made. Other than required by law, we do not undertake any obligation to update them in light of new information or future developments. These forward-looking statements are based upon information, assumptions and estimates available to us as of the date of this press release, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete.

    Coretechs.ai contact:

    Michi Sassa, Chief Financial Officer

    [email protected]

    +1 858 459 9700

    EDAP TMS Company Contact

    Blandine Confort

    Investor Relations / Legal Affairs

    EDAP TMS SA

    +33 4 72 15 31 50

    [email protected]

    EDAP TMS Investor Contact

    John Fraunces

    LifeSci Advisors, LLC

    (917) 355-2395

    [email protected]



    Primary Logo

    Get the next $EDAP alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $EDAP

    DatePrice TargetRatingAnalyst
    5/15/2025Overweight → Neutral
    Piper Sandler
    4/4/2025$2.00Buy → Hold
    Jefferies
    11/1/2022$11.00Buy
    Jefferies
    11/19/2021$12.00 → $11.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $EDAP
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • EDAP to Present at the Jefferies Global Healthcare Conference

      AUSTIN, Texas, May 27, 2025 -- EDAP TMS SA (NASDAQ:EDAP) ("the Company"), the global leader in robotic energy-based therapies, today announced that Ryan Rhodes, Chief Executive Officer, is scheduled to deliver a presentation and host 1x1 investor meetings at the Jefferies Global Healthcare Conference, which is being held June 3-5, 2025, in New York City.  Presentation details: Date:Thursday, June 5th Time:4:20-4:50 PM ET Webcast:https://wsw.com/webcast/jeff319/edap/1824368 The live and archived webcast of the presentation can be accessed in the Investors section of the Company's website here. About EDAP TMS SA A recognized leader in robotic energy-based therapies, EDAP TMS develops, ma

      5/27/25 7:00:00 AM ET
      $EDAP
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • EDAP Reports First Quarter 2025 Financial Results

                Achieved a Record Number of Focal One® Robotic HIFU System Placements for a First Quarter Period Received CE Mark Designation for Focal One for the Treatment of Deep Infiltrating Endometriosis Positive Final Results of FARP Randomized Controlled Trial Presented at American Urology Association Annual Meeting (AUA 2025)Launched the New Focal One i Robotic HIFU System Performed World's First Remote Transcontinental Focal One Robotic HIFU Procedure Successfully AUSTIN, Texas, May 15, 2025 - EDAP TMS SA (NASDAQ:EDAP), the global leader in robotic energy-based therapies, reported today unaudited consolidated financial results for the first quarter of 2025. "Demand for Focal One remai

      5/15/25 7:00:00 AM ET
      $EDAP
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • EDAP to Announce First Quarter 2025 Financial Results on May 15, 2025

      Company to host conference call and webcast on Thursday, May 15th at 8:30am EDT LYON, France, May 1, 2025 -- EDAP TMS SA (NASDAQ:EDAP) ("the Company"), the global leader in robotic energy-based therapies, today announced that it will release its financial results for the first quarter ended March 31, 2025, before the markets open on Thursday, May 15th, 2025. An accompanying conference call and webcast will be conducted by Ryan Rhodes, Chief Executive Officer, Ken Mobeck, Chief Financial Officer, and François Dietsch, Chief Accounting Officer. Please refer to the information below for conference call dial-in information and webcast registration. Call Details: Date:                Thursd

      5/1/25 7:00:00 AM ET
      $EDAP
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $EDAP
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • EDAP TMS SA downgraded by Piper Sandler

      Piper Sandler downgraded EDAP TMS SA from Overweight to Neutral

      5/15/25 1:10:07 PM ET
      $EDAP
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • EDAP TMS SA downgraded by Jefferies with a new price target

      Jefferies downgraded EDAP TMS SA from Buy to Hold and set a new price target of $2.00

      4/4/25 8:36:35 AM ET
      $EDAP
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Jefferies initiated coverage on EDAP TMS SA with a new price target

      Jefferies initiated coverage of EDAP TMS SA with a rating of Buy and set a new price target of $11.00

      11/1/22 6:28:24 AM ET
      $EDAP
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $EDAP
    SEC Filings

    See more
    • SEC Form 6-K filed by EDAP TMS S.A.

      6-K - EDAP TMS SA (0001041934) (Filer)

      6/2/25 4:35:11 PM ET
      $EDAP
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form 6-K filed by EDAP TMS S.A.

      6-K - EDAP TMS SA (0001041934) (Filer)

      5/15/25 7:05:37 AM ET
      $EDAP
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form S-8 filed by EDAP TMS S.A.

      S-8 - EDAP TMS SA (0001041934) (Filer)

      5/14/25 4:36:27 PM ET
      $EDAP
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care